The encyclopedia · Product & Design · Product decision · 2026
Daiichi Sankyo's ADC bet: capacity locked in before the patients existed
Daiichi Sankyo pre-committed dedicated ADC capacity on rosy forecasts. Clinical data shrank demand; the empty lines cost ¥106B in operating profit.
Daiichi Sankyo · 2026-05-08
What happened
Daiichi Sankyo bet its future on DXd antibody-drug conjugates (ADCs), and to feed them it secured manufacturing ahead of demand: part in its own facility, part through contract manufacturers (CMOs) on contracts that carried minimum purchase obligations and reserved dedicated production lines.
When clinical trial results forced revisions to target patient populations and delayed product launches, the demand forecast collapsed. The company was left bound to purchase commitments and idled equipment it no longer needed — a gap it booked as a one-time loss in FY2025 (ending March 31, 2026).
On May 8, 2026 Daiichi Sankyo cut its consolidated operating-profit forecast by ¥106.0 billion: ¥75.7B as a CMO compensation provision, ¥19.3B to impair ADC-related equipment at its Odawara plant and cancel its construction contracts. The patient population never showed up to fill the lines it had ordered.
Why it happened
- Dedicated ADC capacity was committed to CMOs with minimum-purchase obligations before the clinical data was settled
- Trial results shrank target populations and delayed launches, so the locked-in capacity went unused
- FY2025 operating profit was cut ¥106B — ¥75.7B CMO compensation plus ¥19.3B Odawara plant impairment (May 8, 2026)
The lesson
Reserving dedicated production lines and minimum-purchase volumes is a bet on the forecast. If the forecast has a clinical trial, dedicated capacity should be cancellable until the data reads out.
Sources
spotted an error? The club wants to know.
More like this
Yuskin's medical lip cream: a formula that fell below its own approval
Kawasaki Teryx H2: a drive system that throws metal out of the engine bay
Optiray 350: glass and steel in the contrast vial
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.